Can quantitative monitoring of B cells evaluate the efficacy of Rituximab in primary CNS demyelinating disorders?
Introduction: Rituximab (RTX), initially approved for various blood cancers, is additionally used for the management of primary central nervous system (CNS) demyelinating disorders. This study aimed to quantify the % of B cells following RTX therapy in patients with primary CNS demyelinating disorde...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Wolters Kluwer Medknow Publications
2024-01-01
|
| Cyfres: | Annals of Medical Science and Research |
| Pynciau: | |
| Mynediad Ar-lein: | https://journals.lww.com/10.4103/amsr.amsr_36_23 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|